Sugi Predict

Sugi Predict / Compounds / SCHEMBL4715072

SCHEMBL4715072

SCHEMBL4715072

O=C1O[C@]2(CC[C@](O)(C(=O)Nc3ccn(-c4ccccc4)c3)CC2)c2ncccc21

nearest known ligand 0.47

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ NPY5R Q15761 15/20 0.47
▸ LMNA P02545 1/20 0.36
▸ MAPT P10636 1/20 0.34
▸ HSD11B1 P28845 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4715069 1.00 NPY5R (0.47) NPY5RLMNAMAPTHSD11B1L3MBTL1
SCHEMBL4715329 0.85 NPY5R (0.55) NPY5R
SCHEMBL4715330 0.85 NPY5R (0.55) NPY5R
SCHEMBL2659158 0.84 NPY5R (0.64) NPY5R
SCHEMBL2659156 0.84 NPY5R (0.64) NPY5R
SCHEMBL4718174 0.81 NPY5R (0.48) NPY5RLMNAMAPTL3MBTL1
SCHEMBL4718176 0.81 NPY5R (0.48) NPY5RLMNAMAPTL3MBTL1
SCHEMBL4715405 0.79 NPY5R (0.37) NPY5RLMNAMAPTL3MBTL1
SCHEMBL4715403 0.79 NPY5R (0.37) NPY5RLMNAMAPTL3MBTL1
SCHEMBL4715878 0.79 NPY5R (0.54) NPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1483266-B1 SPIRO COMPOUNDS WITH NPY ANTAGONISTIC ACTIVITY BANYU PHARMA CO LTD (JP) 2008-02-27 — — EP claimed
US-20050032820-A1 Novel spiro compounds MSD K.K. (JP) 2005-02-10 — — US claimed
US-6803372-B2 SUCH AS CIS-N-(4-BENZOYLPHENYL)-4-HYDROXY-3'-OXOSPIRO (CYCLOHEXANE-1,1' (3'H)-ISOBENZOFURAN)-4-CARBOXAMIDE FOR USE AS NEUROPEPTIDE Y RECEPTOR ANTAGONIST FOR TREATMENT BULIMIA, OBESITY OR DIABETES BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-10-12 — — US claimed
US-20020188124-A1 Such as cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro (cyclohexane-1,1' (3'H)-isobenzofuran)-4-carboxamide for use as neuropeptide Y receptor antagonist for treatment bulimia, obesity or diabetes MSD K.K. (JP) 2002-12-12 — — US claimed
EP-1483266-B1 SPIRO COMPOUNDS WITH NPY ANTAGONISTIC ACTIVITY BANYU PHARMA CO LTD (JP) 2008-02-27 — — EP disclosed
US-7304072-B2 E.g.,cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide; useful as neuropeptide Y receptor antagonists and as agents for therapy of cardiovascular disorders, central nervous system disorders, metabolic diseases, respiratory and urogenital disorders BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-12-04 — — US disclosed
US-20050032820-A1 Novel spiro compounds MSD K.K. (JP) 2005-02-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020188124-A1 Such as cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro (cyclohexane-1,1' (3'H)-isobenzofuran)-4-carboxamide for use as neuropeptide Y receptor antagonist for treatment bulimia, obesity or diabetes NPY1R, GPR119, NPY2R NPY5R 13/4885LMNA 3598/4885MAPT 4590/4885
US-20050032820-A1 Novel spiro compounds NR3C2, GPR119, NPY2R NPY5R 62/4885LMNA 2471/4885MAPT 2438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.